Currently, an enzyme treatment widely used as a treatment for Gaucher disease is not suitable for the treatment of type III Gaucher disease, which causes neurological symptoms such as epilepsy because it can not pass through the blood-brain barrier and move into the brain tissue. Resveratrol is a natural polyphenol component with various properties such as anti-inflammatory, antioxidant, and neuroprotective effects that pass through the blood-brain barrier. The present inventors evaluated the therapeutic effect of resveratrol on fibroblasts derived from type III Gaucher disease patients. The effects of AIF, Bax, truncated caspase-3, ACAT1, E3BP and CS were evaluated by western immunoblot to evaluate the effect on cell survival rate by MTT assay. In addition, intracellular glucosylceramide (glucocerebroside) concentration of resveratrol-treated cells was confirmed by thin film chromatography. As a result, survival rate of resveratrol-treated cells was significantly increased as compared with control cells. The levels of the apoptotic factors AIF, Bax and truncated caspase-3 after resveratrol treatment decreased in a dose-dependent manner, and the levels of ACAT1, E3BP and CS expression increased in a dose-dependent manner. TLC results showed that glucosyl ceramide, a causative agent of Gaucher disease, was significantly reduced in cells of resveratrol treated type III Gaucher disease patients. These results suggest that resveratrol can reduce cell death and reduce glucosyl ceramide levels and may be used as a treatment for type III Gaucher disease with neurological symptoms.현재 고셔병 치료제로 널리 사용되는 효소치료제는 혈관-뇌 장벽을 통과하지 못해 뇌조직 내로 이동하지 못함으로 인해 간질 등 신경학적 증상을 나타내는 Ⅲ형 고셔병의 치료제로 적합하지 못하다. 레스베라트롤은 항염증, 항산화, 신경보호효과와 같은 다양한 특성을 갖는 천연 폴리페놀 성분으로 혈관-뇌 장벽을 통과한다. 본 발명자는 Ⅲ형 고셔병 환자 유래 섬유아세포에 대한 레스베라트롤의 치료 효과를 평가하였다. 세포 생존율에 미치는 영향을 MTT 분석으로 평가하였고, 고셔병 환자 세포에 미치는 영향을 알아보기 위해 웨스턴 면역블랏으로 AIF, Bax, 절단된 캐스페이즈-3, ACAT1, E3BP 및 CS의 발현 변화를 평가하였다. 또한, 레스베라트롤 처리한 세포의 세포 내 글루코실세라마이드(글루코세레브로사이드) 농도를
